300 related articles for article (PubMed ID: 10482153)
1. Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C).
Glueck CJ; Wang P; Fontaine RN; Tracy T; Sieve-Smith L; Lang JE
Am J Cardiol; 1999 Sep; 84(5):549-54. PubMed ID: 10482153
[TBL] [Abstract][Full Text] [Related]
2. Interaction of estrogen replacement therapy with the thrombophilic 20210 G/A prothrombin gene mutation for atherothrombotic vascular disease: a cross-sectional study of 275 hyperlipidemic women.
Glueck CJ; Wang P; Fontaine RN; Sieve-Smith L; Lang JE
Metabolism; 2001 Mar; 50(3):360-5. PubMed ID: 11230792
[TBL] [Abstract][Full Text] [Related]
3. Estrogen replacement therapy, thrombophilia, and atherothrombosis.
Glueck CJ; Wang P; Fontaine RN; Sieve-Smith L; Lang JE
Metabolism; 2002 Jun; 51(6):724-32. PubMed ID: 12037725
[TBL] [Abstract][Full Text] [Related]
4. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.
Price DT; Ridker PM
Ann Intern Med; 1997 Nov; 127(10):895-903. PubMed ID: 9382368
[TBL] [Abstract][Full Text] [Related]
5. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism.
Haim N; Lanir N; Hoffman R; Haim A; Tsalik M; Brenner B
Am J Med; 2001 Feb; 110(2):91-6. PubMed ID: 11165549
[TBL] [Abstract][Full Text] [Related]
6. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism.
Rodeghiero F; Tosetto A
Ann Intern Med; 1999 Apr; 130(8):643-50. PubMed ID: 10215560
[TBL] [Abstract][Full Text] [Related]
7. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism.
Emmerich J; Rosendaal FR; Cattaneo M; Margaglione M; De Stefano V; Cumming T; Arruda V; Hillarp A; Reny JL
Thromb Haemost; 2001 Sep; 86(3):809-16. PubMed ID: 11583312
[TBL] [Abstract][Full Text] [Related]
8. Combined heterozygous plasminogen deficiency and factor V Leiden defect in the same kindred.
Sartori MT; Simioni P; Patrassi GM; Theodoridis P; Tormene D; Girolami A
Clin Appl Thromb Hemost; 2000 Jan; 6(1):36-40. PubMed ID: 10726047
[TBL] [Abstract][Full Text] [Related]
9. Factor V Leiden mutation is not increased in patients with inflammatory bowel disease.
Zauber NP; Sabbath-Solitare M; Rajoria G; Mogan G
J Clin Gastroenterol; 1998 Oct; 27(3):215-6. PubMed ID: 9802448
[TBL] [Abstract][Full Text] [Related]
10. Resistance to activated protein C--frequent etiologic factor for venous thrombosis.
Simkova M; Simko F; Kovacs L
Bratisl Lek Listy; 2001; 102(5):240-7. PubMed ID: 11725376
[TBL] [Abstract][Full Text] [Related]
11. Activated protein C resistance in patients with peripheral vascular disease.
Sampram ES; Lindblad B; Dahlbäck B
J Vasc Surg; 1998 Oct; 28(4):624-9. PubMed ID: 9786256
[TBL] [Abstract][Full Text] [Related]
12. Factor V Leiden as a common genetic risk factor for venous thromboembolism.
Horne MK; McCloskey DJ
J Nurs Scholarsh; 2006; 38(1):19-25. PubMed ID: 16579319
[TBL] [Abstract][Full Text] [Related]
13. Discrimination between normal wildtype and carriers of coagulation factor V Leiden mutation by the activated protein C resistance test in the presence of factor V deficient plasma.
Reuner KH; Litfin F; Patscheke H
Eur J Clin Chem Clin Biochem; 1997 Jan; 35(1):41-5. PubMed ID: 9156566
[TBL] [Abstract][Full Text] [Related]
14. Resistance to activated protein C (APC): mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients.
Födinger M; Mannhalter C; Pabinger I; Koizar D; Rintelen C; Hörl WH; Sunder-Plassmann G
Nephrol Dial Transplant; 1996 Apr; 11(4):668-72. PubMed ID: 8671856
[TBL] [Abstract][Full Text] [Related]
15. Activated protein C resistance and factor V Leiden mutation can be associated with first-as well as second-trimester recurrent pregnancy loss.
Younis JS; Brenner B; Ohel G; Tal J; Lanir N; Ben-Ami M
Am J Reprod Immunol; 2000 Jan; 43(1):31-5. PubMed ID: 10698038
[TBL] [Abstract][Full Text] [Related]
16. Inherited thrombophilic risk factors and venous thromboembolism: distinct role in peripheral deep venous thrombosis and pulmonary embolism.
Margaglione M; Brancaccio V; De Lucia D; Martinelli I; Ciampa A; Grandone E; Di Minno G
Chest; 2000 Nov; 118(5):1405-11. PubMed ID: 11083693
[TBL] [Abstract][Full Text] [Related]
17. Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism?
Spannagl M; Heinemann LA; Schramm W
Eur J Contracept Reprod Health Care; 2000 Jun; 5(2):105-12. PubMed ID: 10943572
[TBL] [Abstract][Full Text] [Related]
18. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease.
Herrington DM; Vittinghoff E; Howard TD; Major DA; Owen J; Reboussin DM; Bowden D; Bittner V; Simon JA; Grady D; Hulley SB
Arterioscler Thromb Vasc Biol; 2002 Jun; 22(6):1012-7. PubMed ID: 12067913
[TBL] [Abstract][Full Text] [Related]
19. Activated protein C resistance--a major risk factor for thrombosis.
Rosén SB; Sturk A
Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
[TBL] [Abstract][Full Text] [Related]
20. Thrombin generation in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. A pilot study.
Couturaud F; Duchemin J; Leroyer C; Delahousse B; Abgrall JF; Mottier D;
Thromb Haemost; 2008 Jan; 99(1):223-8. PubMed ID: 18217158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
